Regen Medical is a regenerative medicine business focused on wound healing , delivering innovative new technologies and cost effective solutions across burns and woundcare.
Specialising in wound healing within the regenerative field. Part of the Joint Operations family, our dedicated team supports its customers within the burns, wound healing, plastics and regenerative fields.
Experts in allograft, Regen Medical are excited to be offering a ground-breaking product portfolio throughout the UK, including products from MiMedx®
The EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) Allograft from MiMedx is a minimally manipulated natural human amniotic membrane that provides a scaffold for cellular ingrowth, modulates inflammation and reduces scar tissue formation for enhanced healing. An amnion/chorion membrane allograft for homologous use in acute and chronic wound care.
Peer-reviewed publications have demonstrated that PURION processed dHACM recruits stem cells, promotes migration and modulates stem cell activity in vitro and in vivo compared to appropriate controls. EpiFix contains a large and diverse array of 285 regulatory proteins, including growth factors, cytokines, and chemokines that are known to be therapeutic regulators of inflammation, angiogenesis and wound healing.
In a recently published Level 1 study examining the efficacy of EpiFix in conjunction with Standard of Care (SOC) for the treatment of Diabetic Foot Ulcers (DFUs), it was reported that EpiFix demonstrates higher healing rates with a superior wound healing trajectory in a heterogeneous patient population compared with SOC alone (control).
EpiFix is processed using the PURION process, a unique approach that provides an easy to use allograft stored at ambient conditions.
CLICK HERE FOR MORE INFORMATION AND TO ARRANGE TO TRY EPIFIX
1. Tettelbach W, Cazzell S, Reyzelman AM, Sigal F, Caporusso JM, Agnew PS. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2018;1-11.
Patents and patents pending see: www.mimedx.com/patents. Epifix®, PURION®, and MiMedx® are registered U.S. trademarks of MiMedx Group, Inc. 1775 West Oak Commons Court NE, Marietta, GA 30062 2018 MiMedx Group, Inc. All Rights Reserved.
www.mimedx.com EP539.001
Success!